These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 25987234)
21. Prognostic implications of stress modality on mortality risk and cause of death in patients undergoing office-based SPECT myocardial perfusion imaging. Poulin MF; Alexander S; Doukky R J Nucl Cardiol; 2016 Apr; 23(2):202-11. PubMed ID: 25788401 [TBL] [Abstract][Full Text] [Related]
22. Electrocardiographic changes during vasodilator SPECT myocardial perfusion imaging: does it affect diagnosis or prognosis? Azemi T; Rai M; Parwani P; Baghdasarian S; Kazi F; Ahlberg AW; Cyr G; Katten D; O'Sullivan D; Fram D; Heller GV J Nucl Cardiol; 2012 Feb; 19(1):84-91. PubMed ID: 21947978 [TBL] [Abstract][Full Text] [Related]
23. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study. Tejani FH; Thompson RC; Iskandrian AE; McNutt BE; Franks B J Nucl Cardiol; 2011 Feb; 18(1):73-81. PubMed ID: 21082298 [TBL] [Abstract][Full Text] [Related]
24. Differential risk reclassification improvement by exercise testing and myocardial perfusion imaging in patients with suspected and known coronary artery disease. Koh AS; Gao F; Chin CT; Keng FY; Tan RS; Chua TS J Nucl Cardiol; 2016 Jun; 23(3):366-78. PubMed ID: 26358085 [TBL] [Abstract][Full Text] [Related]
25. The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging. Andrikopoulou E; AlJaroudi WA; Farag A; Lester D; Patel H; Iskandrian AE; Hage FG Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1493-502. PubMed ID: 27079736 [TBL] [Abstract][Full Text] [Related]
26. The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol. Thomas GS; Cullom SJ; Kitt TM; Feaheny KM; Ananthasubramaniam K; Gropler RJ; Jain D; Thompson RC J Nucl Cardiol; 2017 Jun; 24(3):788-802. PubMed ID: 28224449 [TBL] [Abstract][Full Text] [Related]
27. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. Mahmarian JJ; Cerqueira MD; Iskandrian AE; Bateman TM; Thomas GS; Hendel RC; Moye LA; Olmsted AW JACC Cardiovasc Imaging; 2009 Aug; 2(8):959-68. PubMed ID: 19679284 [TBL] [Abstract][Full Text] [Related]
28. The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date. Kolkailah AA; Iskander M; Iskander F; Patel PP; Khan R; Doukky R J Nucl Cardiol; 2022 Feb; 29(1):101-110. PubMed ID: 32632913 [TBL] [Abstract][Full Text] [Related]
29. Accuracy of Brophey MD; Farukhi IM; Castanon R; DeLaPena R; Bradshaw L; Banerjee S J Nucl Med Technol; 2017 Jun; 45(2):75-81. PubMed ID: 28408703 [TBL] [Abstract][Full Text] [Related]
30. The prognostic value of regadenoson SPECT myocardial perfusion imaging: The largest cohort to date. Kattoor AJ; Kolkailah AA; Iskander F; Iskander M; Diep L; Khan R; Doukky R J Nucl Cardiol; 2021 Dec; 28(6):2799-2807. PubMed ID: 32383079 [TBL] [Abstract][Full Text] [Related]
31. Incremental prognostic value of (99m)Tc-tetrofosmin myocardial SPECT after percutaneous coronary intervention. Georgoulias P; Tzavara C; Demakopoulos N; Giannakou S; Valotassiou V; Tsougos I; Xaplanteris P; Fezoulidis I Ann Nucl Med; 2008 Dec; 22(10):899-909. PubMed ID: 19142709 [TBL] [Abstract][Full Text] [Related]